Evidence map›Paper›PMID 23430298›Full record

ArticleZeitschrift fur Gerontologie und Geriatrie2013

[Pharmacotherapy of depression in the elderly].

V Holthoff

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Gerontologie und Geriatrie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. [Depression in old age, part 2 : Comorbidity and treatment].Zeitschrift fur Gerontologie und Geriatrie · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

V HolthoffKlinik und Poliklinik für Psychiatrie und Psychotherapie, Deutsches Zentrum für Neurodegenerative Erkrankungen, Partnerstandort Dresden, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. vjera.holthoff@uniklinikum-dresden.de

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is a common condition in older people, affecting in its moderate or severe forms around 4 % of those living in the community. Depression has been shown to also increase the rate of mortality. However, far less is known about depression in old age than in younger or middle age. Depression in the old differs from younger patients in several aspects: comorbid medical conditions, polypharmacy, alterations in age-associated organ function and pharmacodynamic and pharmacokinetic changes and a higher level of drug interactions. These patients also have a higher risk of medication side effects. However, treatment is effective and maintenance therapy can successfully prevent recurrence of depressive episodes. Selective serotonin reuptake inhibitors (SSRI) and selective serotonin-noradrenaline reuptake inhibitors (SNRI) are recommended as first-line treatment for the acute phase and continuation therapy. At least 6 weeks of treatment is necessary to assess the therapeutic effect. Lithium augmentation has been shown to be effective in treatment-refractory depression. Continuation therapy is recommended for at least 9 months and duration of maintenance therapy should be at least 2 years.

Indexed as

AgedAged, 80 and overAntidepressive AgentsDepressionFemaleHumansLithium CompoundsMaleSelective Serotonin Reuptake InhibitorsAntidepressive AgentsLithium CompoundsSelective Serotonin Reuptake Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.